Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Cash (2016 - 2025)

Ultragenyx Pharmaceutical has reported Change in Cash over the past 10 years, most recently at $221.5 million for Q4 2025.

  • Quarterly Change in Cash rose 815.69% to $221.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $252.0 million through Dec 2025, up 820.0% year-over-year, with the annual reading at $252.0 million for FY2025, 820.0% up from the prior year.
  • Change in Cash was $221.5 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $26.1 million in the prior quarter.
  • Over five years, Change in Cash peaked at $367.9 million in Q2 2024 and troughed at -$330.0 million in Q3 2024.
  • The 5-year median for Change in Cash is -$11.3 million (2022), against an average of -$14.5 million.
  • The largest YoY upside for Change in Cash was 2179.24% in 2024 against a maximum downside of 1035.71% in 2024.
  • A 5-year view of Change in Cash shows it stood at $100.0 million in 2021, then plummeted by 358.59% to -$258.7 million in 2022, then soared by 154.11% to $140.0 million in 2023, then plummeted by 82.72% to $24.2 million in 2024, then skyrocketed by 815.69% to $221.5 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Change in Cash are $221.5 million (Q4 2025), $26.1 million (Q3 2025), and $49.5 million (Q2 2025).